智翔金泰股价跌5.61%，东证资管旗下1只基金重仓，持有245.12万股浮亏损失463.27万元

Group 1 - The core point of the article highlights the decline in the stock price of Zhixiang Jintai, which fell by 5.61% to 31.80 CNY per share, with a trading volume of 31.83 million CNY and a turnover rate of 0.84%, resulting in a total market capitalization of 11.66 billion CNY [1] - Zhixiang Jintai, established on October 20, 2015, and listed on June 20, 2023, is primarily engaged in the research, production, and sales of antibody drugs, with 99.96% of its main business revenue coming from drug sales [1] Group 2 - From the perspective of major circulating shareholders, Dongzheng Asset Management's fund is among the top shareholders of Zhixiang Jintai, having reduced its holdings by 92,700 shares in the second quarter, now holding 2.45 million shares, which accounts for 2.1% of circulating shares, resulting in an estimated floating loss of approximately 4.63 million CNY [2] - The fund, Oriental Red Medical Upgrade Stock Initiation A (015052), was established on March 29, 2022, with a latest scale of 481 million CNY, achieving a year-to-date return of 78.01% and a one-year return of 98.05% [2] Group 3 - The fund manager of Oriental Red Medical Upgrade Stock Initiation A is Jiang Qi, who has been in the position for 3 years and 168 days, managing a total fund size of 1.41 billion CNY, with the best fund return during his tenure being 70.01% and the worst being 67.12% [3] Group 4 - In terms of the fund's top heavy positions, Zhixiang Jintai is the eighth largest holding in the Oriental Red Medical Upgrade Stock Initiation A fund, with the fund holding 2.45 million shares, which represents 4.82% of the fund's net value, and an estimated floating loss of about 4.63 million CNY [4]